Chronic myeloid leukemia with e19a2 (c3a2) BCR/ABL fusion junction -is it truly a benign disease?
TO THE EDITOR There have been proposals recently to identify a particular CML variant -neutrophilic-chronic myeloid leukemia (CML-N) in association with a distinctive molecular defect -BCR/ABL hybrid gene transcript with an e19a2(c3a2) junction. [1] [2] [3] [4] CML-N is believed to run a much more benign course than classical CML and only one patient of the nine reported to date has transformed to blastic crisis. We report a patient who presented initially with CML in chronic course and possessed the e19a2 type of BCR/ABL, but had atypical features and subsequently progressed to accelerated phase.
WYL, a 29-year-old female engineer presented in December 1996 with a 2-month history of persistent fever and weight loss of 3 kg. She had previously been in good health. Physical examination revealed marked splenomegaly of 15 cm. The peripheral blood count showed hemoglobin (Hb) 9.4 g/dl, leukocyte count (WBC) 205 × 10 9 /l (no blasts), platelet (plt) 627 × 10 9 /l. Neutrophil alkaline phosphatase (NAP) score was zero. A bone marrow aspirate was consistent with chronic myeloid leukemia in chronic phase with mainly granulocytic cells seen. Bone marrow biopsy showed increased cellularity with plentiful megakaryocytes and also considerable intervening fibrosis with diffuse increase in reticulin fibers. Cytogenetic studies revealed presence of extra Philadelphia (Ph) chromosome. She was started on hydroxyurea with subsequent addition of alpha-interferon. Three weeks later, there was regression of splenomegaly and normalization of white cell counts. She was referred to our institution for allogeneic bone marrow transplant. A bone marrow aspirate pretransplant in February 1997 had 28% blasts consistent with accelerated phase. Immunophenotyping showed that the blasts expressed CD13 and CD33. The blood count then: Hb 9.6 g/dl, WBC 10.4 × 10 9 /l (neutrophils 65%, lymphocytes 20%, monocytes 9%, basophils 2%, metamyelocytes 2%, myelocytes 2% and 0.3% blasts), plt 723 × 10 9 /l. Karyotypic analysis revealed Ph chromosome in seven metaphases with an additional Ph chromosome in one cell (similar to changes found at diagnosis). Chemotherapy with idarubicin 12 mg/m 2 for 2 days and cytosine arabinoside 100 mg/m 2 for 5 days was commenced. No blasts were detected in a repeat bone marrow aspirate and biopsy 6 weeks post-chemotherapy. However, her spleen remained enlarged at 6 cm. She successfully underwent allogeneic BMT in April 1997. Cytogenetic analysis 1 month post-BMT showed normal karyotype. Unfortunately she died 90 days post-BMT of fulminant sepsis with pneumonia.
Pre-BMT, reverse-transcription polymerase chain reaction (RT-PCR) analysis with primers specific to the M-bcr region and m-bcr region 5, 6 was performed on blood and marrow samples. For the M-bcr region, the expected b2a2 or b3a2 type of transcripts of CML which would yield PCR products of 455 bp and 530 bp, respectively, were not observed. A much bigger PCR product of about 1000 bp was obtained. We sus-pected our patient might have the e19a2 transcript which contains an additional BCR sequence of 540 bp. 4 This was confirmed by cloning and nucleotide sequence analysis of the amplified product. No PCR product of 444 bp expected for the e1a2 transcript was obtained.
Southern DNA analysis of the M-bcr region using the bcr Probe-1 (Oncogene Science, NY, USA) or the bigger Transprobe Pr-1 (Oncogene Science) which covers the entire 5.8 kb M-bcr region failed to show any rearrangement band in all digests (Bgl/II, Xbal, HindIII, BamHl, EcoRl, Sstl) tested. This is our first case detected to have an e19a2 transcript out of 200 CML patients with BCR/ABL transcript. Our patient did not have any concurrent b2a2 or b3a2 transcripts. Although possessing this specific e19a2 genotype, there were several atypical features. At presentation, she had extremely elevated white cell counts and massive splenomegaly and absent NAP score. This brings to mind a case reported by Wilson et al 7 who described a patient with e19a2 transcript but clinical features consistent with classical CML.
Though morphologically in chronic phase at the time of presentation, 2 months later our patient was in accelerated phase. Only one other patient 2 has been reported whose disease progressed 2 years following presentation -a 50-yearold female with Philadelphia chromosome and isochromosome 17 q at diagnosis. Thus both cases had additional cytogenetic abnormalities other than the Philadelphia chromosome at diagnosis.
Could our patient have been in chronic phase for some time and presented at the point when her disease was transforming? We do not know. However we share the viewpoint of Emilia et al 8 and Mittre et al 9 that it is premature to claim any conclusion regarding the e19a2 genotype/phenotype relationship. Further studies on long-term outcome and characterization of 
ETV6/ABL fusion is rare in Ph-negative chronic myeloid disorders

TO THE EDITOR
The ETV6 gene (previously TEL) located on chromosome band 12p13 was initially identified as a fusion partner to PDGFRB in chronic myelomonocytic leukemia (CMML). 1 Since then, ETV6 has been shown to be rearranged in several hematologic malignancies and has, to date, been shown to fuse with the ABL, CBFA2, EVI1, JAK2, MDS1, MN1 and STL genes in different myeloid as well as lymphoid neoplastic disorders and, very recently, with NTRK3 in congenital fibrosarcoma. [1] [2] [3] [4] Until now, ETV6 is the only known gene, apart from BCR, that fuses to ABL, and this chimeric transcript has so far been reported in single cases of acute leukemias, ie acute undifferentiated leukemia and pediatric acute lymphoblastic leukemia (ALL). 1 We recently described a submicroscopic fusion of these genes in a Philadelphia (Ph)-and BCR/ABL-negative
